公开(公告)号：EP2555770A1

公开(公告)日：2013-02-13

申请号：EP11715353.6

申请日：2011-04-06

申请人： Allergan, Inc.

发明人： GRAHAM, Richard, S. ,  HOLLANDER, David ,  VILLANUEVA, Linda ,  FARNES, Eldon, Quinn ,  ATTAR, Mayssa ,  SCHIFFMAN, Rhett, M. ,  CHANG, Chin-Ming ,  WELTY, Devin, F.

IPC分类号： A61K31/407 ,  A61P27/02

CPC分类号： A61K9/0048 ,  A61K9/08 ,  A61K31/407 ,  A61K47/38

摘要： The present invention is directed to an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose which promotes epithelial wound healing in a patients cornea.

摘要翻译： 本发明涉及一种含有有效量的酮咯酸的水性眼用溶液，其包含促进患者角膜上皮创面愈合的羧甲基纤维素。

公开(公告)号：EP1670467A1

公开(公告)日：2006-06-21

申请号：EP04785301.5

申请日：2004-10-01

申请人： ALLERGAN, INC.

发明人： SHEN, Jie ,  WELTY, Devin, F. ,  TANG-LIU, Diane, D.

IPC分类号： A61K31/44 ,  A61P1/04

CPC分类号： A61K31/4439

摘要： Oral dosage forms, methods of treating diseases or adverse conditions, and methods of inhibiting gastric acid secretion related to prodrugs of a proton pump inhibitor are disclosed herein. Certain embodiments relate to the membrane permeability of the proton pump inhibitor and/or the membrane permeability of the prodrug. Other embodiments relate to prodrugs comprising an acidic functional group and a sulfonyl moiety. In other embodiments, the prodrug is a carboxylic acid which comprises a phenylsulfonyl moiety. Other embodiments relate to the pH of dosage forms and dosage forms comprising salts of acidic functional groups.

公开(公告)号：EP2555770B1

公开(公告)日：2017-11-01

申请号：EP11715353.6

申请日：2011-04-06

申请人： ALLERGAN, INC.

发明人： GRAHAM, Richard, S. ,  HOLLANDER, David ,  VILLANUEVA, Linda ,  FARNES, Eldon, Quinn ,  ATTAR, Mayssa ,  SCHIFFMAN, Rhett, M. ,  CHANG, Chin-Ming ,  WELTY, Devin, F.

IPC分类号： A61K31/407 ,  A61P27/02 ,  A61K9/00 ,  A61K9/08 ,  A61K47/38

CPC分类号： A61K9/0048 ,  A61K9/08 ,  A61K31/407 ,  A61K47/38

公开(公告)号：EP1722794A1

公开(公告)日：2006-11-22

申请号：EP05724537.5

申请日：2005-03-03

申请人： ALLERGAN, INC.

发明人： SHEN, Jie ,  WELTY, Devin, F. ,  TANG-LIU, Diane, D.

IPC分类号： A61K31/4439 ,  A61K38/06 ,  A61P1/04 ,  A61K31/4704

CPC分类号： A61K31/4704 ,  A61K31/4439 ,  A61K38/06 ,  A61K45/06 ,  A61K2300/00

摘要： A method comprising orally administering to a mammal a proton pump inhibitor, or a pharmaceutically acceptable prodrug thereof, and a compound which modulates the activity of the MRP2 or other transporter proteins involved in efflux of a proton pump inhibitor or a prodrug, is disclosed herein, said method being effective for the prevention or treatment of a disease or condition related to gastric acid secretion. This method applied to compounds which both inhibit and stimulate MRP2 activity or activity of other transporter proteins involved in efflux of a proton pump inhibitor or a prodrug. Compositions, medicaments, and experimental results related thereto are also disclosed.